Application of carbohydrates in approved small molecule drugs: A review

H Jiang, X Qin, Q Wang, Q Xu, J Wang, Y Wu… - European Journal of …, 2021 - Elsevier
Carbohydrates are an important energy source and play numerous key roles in all living
organisms. Carbohydrates chemistry involved in diagnosis and treatment of diseases has …

Targeting platelet receptor function in thrombus formation: the risk of bleeding

F Swieringa, MJE Kuijpers, JWM Heemskerk… - Blood reviews, 2014 - Elsevier
In this review, we presume that the process of thrombus formation, as assessed in whole
blood flow studies and in experimental (murine) thrombosis studies, reflects the platelet …

Purinergic signaling in myocardial ischemia–reperfusion injury

Y Zhuang, M Yu, S Lu - Purinergic Signalling, 2023 - Springer
Purines and their derivatives, extensively distributed in the body, act as a class of
extracellular signaling molecules via a rich array of receptors, also known as purinoceptors …

Platelets and Cardioprotection: the role of nitric oxide and carbon oxide

I Russo, C Barale, E Melchionda, C Penna… - International Journal of …, 2023 - mdpi.com
Nitric oxide (NO) and carbon monoxide (CO) represent a pair of biologically active gases
with an increasingly well-defined range of effects on circulating platelets. These gases …

Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX)

M Marino, D Rizzotti, S Leonardi - Current cardiology reports, 2014 - Springer
Platelet inhibition is the main goal of ancillary pharmacologic therapy during percutaneous
coronary interventions (PCI). Thienopyridines and ticagrelor are oral drugs developed for …

Perioperative management of patient with intracoronary stent presenting for noncardiac surgery

I Gurajala, R Gopinath - Annals of cardiac anaesthesia, 2016 - journals.lww.com
As the number of percutaneous coronary interventions increase annually, patients with
intracoronary stents (ICS) who present for noncardiac surgery (NCS) are also on the rise …

Meta-analysis of comparison of the newer P2Y12 inhibitors (oral preparation or intravenous) to clopidogrel in patients with acute coronary syndrome

L Zhang, J Lu, W Dong, H Tian, W Feng… - Journal of …, 2017 - journals.lww.com
Aims: New P2Y 12 adenosine diphosphate receptor antagonists have been used in the
treatment of acute coronary syndrome (ACS) with different results. This systematic review …

Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data

E Tamborini Permunian, N Riva, L Guasti… - Expert Opinion on …, 2015 - Taylor & Francis
Introduction: Dual antiplatelet therapy is the standard of care for patients with acute coronary
syndromes or with recent coronary stents implantation. P2Y12 receptor antagonists have …

[HTML][HTML] Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies

M Jia, Z Li, H Chu, L Li, K Chen - Medical Science Monitor …, 2015 - ncbi.nlm.nih.gov
Background Whether prasugrel can take the place of clopidogrel for patients with acute
coronary syndrome (ACS) is not clear. The aim of this study was to perform a meta-analysis …

10 Tips for Planning and Publishing Clinical Research

V Monica, G Biondi-Zoccai, V Poonam - JACC: Advances, 2023 - pmc.ncbi.nlm.nih.gov
Scientific research is complementary to clinical activity and can be beneficial for both
cardiovascular trainees and established cardiologists. Research forces clinicians to think …